

Algenex enters biocomponents market to provide mammalian-free production of cost efficient high-quality proteins and peptides

Proven technology poised to accelerate growth of emerging synthetic food space

Madrid (Spain), September 30, 2021 – Algenex SL, a biotech company delivering disruptive technologies for recombinant biologics production, has announced its entry into the biocomponents market at the Biospain 2021 conference in Pamplona. Algenex intends to provide a high quality, lower cost alternative to traditional methods through its automated and bioreactor-free expression platform, CrisBio®, which harnesses the power of insects as natural single-use bioreactors.

Algenex already has an established track record as a producer of proteins for the human and animal diagnostic and therapeutic markets and has also demonstrated the applicability of its technology platform to growth factors, hormones, enzymes and cytokines.

Claudia Jiménez, CEO of Algenex, commented, *“This new business path represents an important step forward for Algenex. We have shown that our technology can be applied to a wide range of important biocomponent classes and have also recently received EMA validation for the first vaccine produced using our CrisBio® platform, highlighting its robustness.”*

Algenex has already signed commercial agreements for the use of Crisbio® in the production of antigens with diagnostic companies, including Biokit and GlobalDX. With the latter, Algenex markets an African swine fever antibody detection test based on antigens produced using CrisBio®. These agreements demonstrate the ability of Algenex to meet commercial requirements for biocomponent supply for international markets.

Building on this platform, the Company intends to expand into the supply of enzymes and growth factors, which are important components in a wide range of biopharmaceutical products including synthetic food, an area of increasing demand and limited market supply. Algenex’ bioreactor-free platform offers ready scalability bringing both cost and product quality benefits to customers. The Company has extensive experience in the production of growth factors, including FGF, EGF and TGF. The overall market for growth factors is expected to reach US\$3.7bn by 2031.

Dr. José Escribano, scientific director and founder of Algenex said: *“The current biocomponents supply chain leaves many innovators, including those in the synthetic food space, unable to secure high quality products at a volume and price that meets their needs. Our technology can solve this problem and provide a disruptive, yet robust alternative to traditional suppliers.”*

Algenex has also proven its technology for the production of a range of enzymes, including DNA polymerase and telomerase. These enzymes, produced using CrisBio®, have equal or superior functionality to commercial offerings, which in addition to the capacity for rapid and scalable production and lower cost of production makes a compelling business case in this area.



For further information, please contact:

Algenex contact

Claudia Jiménez

CEO

T: +34 91 452 4941

cjimenez@algenex.com

Consilium Strategic Communications

Chris Gardner / Chris Welsh

algenex@consilium-comms.com

About Algenex

Algenex is a biotechnology company backed by Cleon Capital and Columbus Venture Partners developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex' first two platforms, TopBac® and CrisBio®, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate linear scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient. The Company's technology is highly applicable across a wide range of commercial product classes in both human and animal health.

Algenex has successfully produced >200 molecules in collaboration with public and private partners, including multiple international pharmaceutical companies, including VLPs, monomeric vaccines, single domain antibodies, hormones, enzymes, growth factors and diagnostic reagents.

For more information, please visit <http://www.algenex.com>